Kyverna Therapeutics, Inc. (KYTX)
| Market Cap | 516.93M +438.8% |
| Revenue (ttm) | n/a |
| Net Income | -156.40M |
| EPS | -3.23 |
| Shares Out | 60.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,426,819 |
| Open | 9.34 |
| Previous Close | 9.49 |
| Day's Range | 8.39 - 9.56 |
| 52-Week Range | 2.06 - 13.67 |
| Beta | 2.06 |
| Analysts | Strong Buy |
| Price Target | 30.40 (+255.97%) |
| Earnings Date | May 12, 2026 |
About KYTX
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreemen... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KYTX stock is "Strong Buy." The 12-month stock price target is $30.4, which is an increase of 255.97% from the latest price.
News
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
Kyverna Therapeutics (KYTX) announced the appointment of Greg Martini as CFO, effective May 18. Martini succeeds Marc Grasso who will be consulting for the company to ensure a transition. With…
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth
Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Kyverna Therapeutics (KYTX) to $25 from $20 and keeps a Buy rating on the shares. Following a discussion with…
Kyverna Therapeutics to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with a...
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
JPMorgan analyst Brian Cheng lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $29 from $30 and keeps an Overweight rating on the shares. The firm updated the company’s…
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
Kyverna reported a net loss of $39.7M for the first quarter ended March 31. Research and development expenses were $30.1M, while general and administrative expenses were $11.3M for the period.
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
Kyverna Therapeutics (KYTX) announced the appointment of veteran commercial leader Nadia Dac as chief commercial officer, effective May 4. Dac most recently served as chief commercial officer at Omero...
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with a...
Kyverna Therapeutics Transcript: Status update
Miv-cel showed rapid, durable, and clinically meaningful improvements in SPS and gMG, with a strong safety profile and the potential to eliminate chronic immunotherapies. Launch strategy targets high-need SPS patients at specialized centers, with robust physician support and regulatory momentum.
Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel
Kyverna Therapeutics (KYTX) announced positive primary analysis results from its registrational trial, KYSA-8, of miv-cel in stiff person syndrome. The data will be presented today in a late-breaking ...
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS
Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel
Kyverna Therapeutics (KYTX) announced positive longer-term follow-up data from the Phase 2 portion of its registrational KYSA-6 trial of miv-cel in patients with generalized myasthenia gravis. The dat...
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for pati...
Kyverna Therapeutics files $300M mixed securities shelf
16:24 EDT Kyverna Therapeutics (KYTX) files $300M mixed securities shelf
Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)
Kyverna reported $279.3M in cash, cash equivalents, and marketable securities as of December 31, 2025. The company expects to have a cash runway into 2028, funding its SPS BLA filing…
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026
Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Transformative pivotal data for miv-cel in stiff person syndrome showed disease reversal and strong safety, with BLA filing and launch targeted for this year. Pipeline expansion includes myasthenia gravis and progressive MS, supported by robust manufacturing and a focused commercial strategy.
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS)
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune dise...
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
Kyverna Therapeutics (KYTX) announced the appointments of Sravan Emany and Andrew Miller, Ph.D. to its Board of Directors. Emany will assume the role of Audit Committee Chair, following the transition...
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization
Kyverna Therapeutics appoints Pujols as Chief Technology Officer
Kyverna Therapeutics (KYTX) announced the appointment of Mayo Pujols as its Chief Technology Officer, CTO, effective February 9, 2026. Most recently, Pujols served as Chief Operating Officer of Castle...
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune disea...